Medicine & Life Sciences
Hepacivirus
100%
Ribavirin
53%
HIV
41%
Chronic Hepatitis C
39%
Hepatitis C
37%
Sofosbuvir
28%
Genotype
27%
Virus Diseases
24%
Antiviral Agents
22%
Sustained Virologic Response
21%
Coinfection
18%
Therapeutics
17%
Interferons
16%
Fibrosis
14%
sofosbuvir drug combination ledipasvir
14%
peginterferon alfa-2a
13%
Infections
12%
Liver Diseases
11%
Hepatitis B virus
10%
velpatasvir
10%
Safety
10%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
9%
RNA
8%
Liver
8%
HIV Infections
7%
ABT-450
7%
ABT-333
7%
ABT-267
7%
Pharmaceutical Preparations
6%
Ritonavir
6%
telaprevir
6%
peginterferon alfa-2b
6%
Protease Inhibitors
5%
HIV-1
5%
Confidence Intervals
5%
Placebos
5%